JP2019534269A - Ｃｓｆ−１ｒの阻害剤を使用して眼疾患を治療するための方法 - Google Patents

Ｃｓｆ−１ｒの阻害剤を使用して眼疾患を治療するための方法 Download PDF

Info

Publication number
JP2019534269A
JP2019534269A JP2019519762A JP2019519762A JP2019534269A JP 2019534269 A JP2019534269 A JP 2019534269A JP 2019519762 A JP2019519762 A JP 2019519762A JP 2019519762 A JP2019519762 A JP 2019519762A JP 2019534269 A JP2019534269 A JP 2019534269A
Authority
JP
Japan
Prior art keywords
compound
composition
pharmaceutically acceptable
acceptable salt
csf
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2019519762A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019534269A5 (enExample
Inventor
エム． アダムス，クリストファー
エム． アダムス，クリストファー
宗人 茂木
宗人 茂木
ヘドリック プア，ステファン
ヘドリック プア，ステファン
マイケル ラムジー，ティモシー
マイケル ラムジー，ティモシー
ウー，へンリー
ザン，チン
Original Assignee
ノバルティス アーゲー
ノバルティス アーゲー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ノバルティス アーゲー, ノバルティス アーゲー filed Critical ノバルティス アーゲー
Publication of JP2019534269A publication Critical patent/JP2019534269A/ja
Publication of JP2019534269A5 publication Critical patent/JP2019534269A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Ophthalmology & Optometry (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • Endocrinology (AREA)
  • Mycology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2019519762A 2016-10-14 2017-10-13 Ｃｓｆ−１ｒの阻害剤を使用して眼疾患を治療するための方法 Pending JP2019534269A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662408345P 2016-10-14 2016-10-14
US62/408,345 2016-10-14
PCT/IB2017/056380 WO2018069893A1 (en) 2016-10-14 2017-10-13 Methods for treating ocular disease using inhibitors of csf-1r

Publications (2)

Publication Number Publication Date
JP2019534269A true JP2019534269A (ja) 2019-11-28
JP2019534269A5 JP2019534269A5 (enExample) 2020-11-26

Family

ID=60569957

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2019519762A Pending JP2019534269A (ja) 2016-10-14 2017-10-13 Ｃｓｆ−１ｒの阻害剤を使用して眼疾患を治療するための方法

Country Status (10)

Country Link
US (1) US10537563B2 (enExample)
EP (1) EP3525819A1 (enExample)
JP (1) JP2019534269A (enExample)
KR (1) KR20190069459A (enExample)
CN (1) CN109789209A (enExample)
AU (1) AU2017342240A1 (enExample)
CA (1) CA3037116A1 (enExample)
IL (1) IL265596A (enExample)
RU (1) RU2019114205A (enExample)
WO (1) WO2018069893A1 (enExample)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20210046002A1 (en) * 2018-03-05 2021-02-18 Massachusetts Eye And Ear Infirmary Amelioration of autoimmune uveitis through blockade of csf1r

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002543093A (ja) * 1999-04-28 2002-12-17 ボード オブ リージェンツ， ザ ユニバーシティ オブ テキサス システム Ｖｅｇｆの選択的阻害による癌処置のための組成物および方法
JP2006520805A (ja) * 2003-03-21 2006-09-14 アムジエン・インコーポレーテツド 複素環式化合物ならびにその使用方法
JP2009534410A (ja) * 2006-04-19 2009-09-24 ノバルティス アクチエンゲゼルシャフト ６−ｏ−置換ベンゾオキサゾールおよびベンゾチアゾール化合物ならびにｃｓｆ−１ｒシグナル伝達を阻害する方法
JP2014513136A (ja) * 2011-05-05 2014-05-29 ノバルティス アーゲー 脳腫瘍の処置用のｃｓｆ−１ｒ阻害剤

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW200640443A (en) * 2005-02-23 2006-12-01 Alcon Inc Methods for treating ocular angiogenesis, retinal edema, retinal ischemia, and diabetic retinopathy using selective RTK inhibitors
AR062239A1 (es) 2007-08-07 2008-10-22 Civil De Estudios Superiores A Composicion farmaceutica sinergica util para inhibir la neovascularizacion (angiogenesis) corneal y retinal, y de otros organos, en un humano o animal
JO3265B1 (ar) 2008-12-09 2018-09-16 Novartis Ag مثبطات بيريديلوكسى اندولات vegf-r2 واستخدامها لعلاج المرض

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002543093A (ja) * 1999-04-28 2002-12-17 ボード オブ リージェンツ， ザ ユニバーシティ オブ テキサス システム Ｖｅｇｆの選択的阻害による癌処置のための組成物および方法
JP2006520805A (ja) * 2003-03-21 2006-09-14 アムジエン・インコーポレーテツド 複素環式化合物ならびにその使用方法
JP2009534410A (ja) * 2006-04-19 2009-09-24 ノバルティス アクチエンゲゼルシャフト ６−ｏ−置換ベンゾオキサゾールおよびベンゾチアゾール化合物ならびにｃｓｆ−１ｒシグナル伝達を阻害する方法
JP2014513136A (ja) * 2011-05-05 2014-05-29 ノバルティス アーゲー 脳腫瘍の処置用のｃｓｆ−１ｒ阻害剤

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
BMC CELL BIOLOGY, vol. 12, JPN6021029187, 2011, pages 5, ISSN: 0004742921 *
J. EXP. MED., vol. 206, no. 5, JPN6021029189, 2009, pages 1089 - 1102, ISSN: 0004742920 *

Also Published As

Publication number Publication date
RU2019114205A (ru) 2020-11-16
AU2017342240A1 (en) 2019-04-04
KR20190069459A (ko) 2019-06-19
CN109789209A (zh) 2019-05-21
CA3037116A1 (en) 2018-04-19
WO2018069893A1 (en) 2018-04-19
US10537563B2 (en) 2020-01-21
US20190231765A1 (en) 2019-08-01
IL265596A (en) 2019-05-30
EP3525819A1 (en) 2019-08-21

Similar Documents

Publication Publication Date Title
JP7774170B2 (ja) 翼状片を治療するための組成物及び方法
US20240140942A1 (en) Fluorinated integrin antagonists
AU2017326791B2 (en) Medicinal composition
WO2021170811A1 (en) Method of treating eye disease using trpv4 antagonists
JP2019534269A (ja) Ｃｓｆ−１ｒの阻害剤を使用して眼疾患を治療するための方法
HK40069641A (en) Compositions and methods for treating pterygium
HK1248677B (en) Fluorinated integrin antagonists
HK1256602B (en) Compositions and methods for treating pterygium
HK1217696B (en) Fluorinated integrin antagonists

Legal Events

Date Code Title Description
A524 Written submission of copy of amendment under article 19 pct

Free format text: JAPANESE INTERMEDIATE CODE: A524

Effective date: 20201013

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20201013

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20210719

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20210803

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20211101

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20211224

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220202

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20220405

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220805

C60 Trial request (containing other claim documents, opposition documents)

Free format text: JAPANESE INTERMEDIATE CODE: C60

Effective date: 20220805

C11 Written invitation by the commissioner to file amendments

Free format text: JAPANESE INTERMEDIATE CODE: C11

Effective date: 20220816

C27A Decision to dismiss

Free format text: JAPANESE INTERMEDIATE CODE: C2711

Effective date: 20221004

C30A Notification sent

Free format text: JAPANESE INTERMEDIATE CODE: C3012

Effective date: 20221115